SANGAMO THERAPEUTICS, INC
No enriched coverage for $SGMOQ in the last 7 days.
No SEC Form 4 filings for $SGMOQ in the last 30 days.
See all $SGMOQ insider activity →SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2
Sangamo Therapeutics (SGMOQ) sold its Fabry disease gene therapy program to PTC Therapeutics for $111M upfront, with up to $100M in milestones. The deal is part of Sangamo's Chapter 11 restructuring, with a bankruptcy court hearing scheduled for September 10, 2026. The transaction is subject to court approval and regulatory milestones.
SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K under the heading “PTC Asset Purchase Agreement” is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. As previously announc
Recent SGMOQ coverage spans mergers & acquisitions and corporate actions.
The filing confirms asset disposition in Chapter 11, indicating ongoing restructuring and potential dilution for existing shareholders.
The cash infusion aids Sangamo’s Chapter 11 restructuring and may lift the distressed stock.
The asset sale removes Sangamo's Fabry disease program and associated liabilities, providing immediate cash but reducing future upside.
AlphAI scores every news story that mentions SGMOQ with an AI model for sentiment and relevance, and aggregates insider trades from SANGAMO THERAPEUTICS, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2
1 min readSangamo Therapeutics (SGMOQ) sold its Fabry disease gene therapy program to PTC Therapeutics for $111M upfront, with up to $100M in milestones. The deal is part of Sangamo's Chapter 11 restructuring, with a bankruptcy court hearing scheduled for September 10, 2026. The transaction is subject to court approval and regulatory milestones.
2 min readSANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K under the heading “PTC Asset Purchase Agreement” is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. As previously announc
2 min read
